DE69801660T2 - Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 - Google Patents

Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Info

Publication number
DE69801660T2
DE69801660T2 DE69801660T DE69801660T DE69801660T2 DE 69801660 T2 DE69801660 T2 DE 69801660T2 DE 69801660 T DE69801660 T DE 69801660T DE 69801660 T DE69801660 T DE 69801660T DE 69801660 T2 DE69801660 T2 DE 69801660T2
Authority
DE
Germany
Prior art keywords
psoriasis
antibodies against
neutralizing antibodies
local treatment
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69801660T
Other languages
English (en)
Other versions
DE69801660D1 (de
Inventor
Q Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yes Biotech Laboratories Ltd
Original Assignee
Yes Biotech Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yes Biotech Laboratories Ltd filed Critical Yes Biotech Laboratories Ltd
Application granted granted Critical
Publication of DE69801660D1 publication Critical patent/DE69801660D1/de
Publication of DE69801660T2 publication Critical patent/DE69801660T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69801660T 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 Expired - Lifetime DE69801660T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97112184A CN1068524C (zh) 1997-06-23 1997-06-23 一种治疗顽症牛皮癣的药物
PCT/CA1998/000604 WO1998058671A1 (en) 1997-06-23 1998-06-23 Topical treatment of psoriasis using neutralizing antibodies to il-8

Publications (2)

Publication Number Publication Date
DE69801660D1 DE69801660D1 (de) 2001-10-18
DE69801660T2 true DE69801660T2 (de) 2002-06-06

Family

ID=5172124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69801660T Expired - Lifetime DE69801660T2 (de) 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Country Status (9)

Country Link
US (1) US20030077283A1 (de)
EP (1) EP0991423B1 (de)
CN (1) CN1068524C (de)
AT (1) ATE205401T1 (de)
AU (1) AU727937B2 (de)
CA (1) CA2291144C (de)
DE (1) DE69801660T2 (de)
ES (1) ES2164434T3 (de)
WO (1) WO1998058671A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379274A4 (de) * 2001-03-23 2006-02-15 Univ Texas Verfahren zur hemmung von angiogenese, tumorwachstum und metastasen mit voll humanem anti-il8 und anti-muc18 bei diversen tumortypen
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
NO2406399T3 (de) * 2009-03-09 2018-07-14
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
EP2982689B1 (de) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
CN105521489A (zh) * 2014-09-28 2016-04-27 徐州逸仕生物技术有限公司 抗人TNF-αIgY抗体及其治疗皮肤疾病的应用
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
JP2021518343A (ja) 2018-03-15 2021-08-02 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
JPH08277299A (ja) * 1995-04-06 1996-10-22 Fujirebio Inc 抗ｉｌ−８抗体、抗ｉｌ−８モノクローナル抗体を産生するハイブリドーマ及び該抗体を用いたｉｌ−８の測定方法
BR9713498A (pt) * 1996-11-08 2000-02-29 Idec Pharma Corp Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos

Also Published As

Publication number Publication date
CA2291144A1 (en) 1998-12-30
EP0991423A1 (de) 2000-04-12
CN1203105A (zh) 1998-12-30
US20030077283A1 (en) 2003-04-24
CN1068524C (zh) 2001-07-18
CA2291144C (en) 2001-07-03
AU727937B2 (en) 2001-01-04
WO1998058671A1 (en) 1998-12-30
ES2164434T3 (es) 2002-02-16
ATE205401T1 (de) 2001-09-15
EP0991423B1 (de) 2001-09-12
AU8096298A (en) 1999-01-04
DE69801660D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE69132575D1 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
AP9801416A0 (en) Method Of treating a plant disease.
DE69825395D1 (de) Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition